<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784443</url>
  </required_header>
  <id_info>
    <org_study_id>P78912</org_study_id>
    <nct_id>NCT03784443</nct_id>
  </id_info>
  <brief_title>Combined Ranibizumab and Iluvien for Diabetic Macular Oedema</brief_title>
  <acronym>CASSIE</acronym>
  <official_title>Combined Anti-VEGF Intravitreal Injections With Sustained Steroid Implantation for the Treatment of Diabetic Macular Oedema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial investigated whether adding Iluvien sustained release steroid intravitreal eye
      implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor)
      intravitreal eye injection treatment for diabetic macular oedema would improve disease
      stability and reduce the need for regular anti-VEGF intravitreal eye injections over first
      two years. Diabetic macular oedema, accumulation of microscopic fluid at the back of the eye,
      is a major cause of poor vision in patients with diabetes.

      This is a double mask randomized control multisite trial, to be conducted at 10 NHS hospital
      eye clinics in England.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit 58 participants in a double-masked, multi-centre, sham-controlled
      clinical trial. Participants will receive Iluvien implantation or sham implantation (masked)
      with a concomitant intravitreal injection of ranibizumab at baseline with an allocation ratio
      of 1:1. This is followed by regular monthly clinic review and repeat intravitreal ranibizumab
      injections to the study eye according to a PRN (pro re nata) treatment protocol.

      This trial aims to evaluate whether Iluvien implantation in addition to standard anti-VEGF
      injection treatment for diabetic macular oedema in pseudophakic eyes will show similar visual
      acuity outcomes but with an improved reduction in CRT (Central Retinal Thickness) while
      reducing the average number of intravitreal injections during the first 2 years of treatment,
      due to the continual micro-dosing of Iluvien therapy.

      Participants meeting all the eligibility criteria will be randomized to either Iluvien
      implant or sham implant procedure with an allocation ratio of 1:1. Participants assigned to
      either treatment arms will receive intravitreal injection of ranibizumab after Iluvien
      implantation or sham implantation at the same baseline visit.

      To maintain double-masking, participants assigned to the control arm will receive sham
      implantation. This will be performed with an empty Luer Lock Syringe without a needle
      attached to it, that will not penetrate the eye nor deliver any drug. Patients assigned to
      either treatment arm will receive ranibizumab intravitreal injection to the study eye at
      baseline 30 minutes after the Iluvien or sham implantation. The sham injection should be
      performed by the unmasked investigator. The unmasked investigator should not be involved in
      any patient assessment in the study.

      Participants will be followed up monthly for 2 years. Participants from both arms will
      receive compulsory Ranibizumab injection during the first three monthly visit and followed by
      monthly Ranibizumab as per PRN protocol. The end of study visit should take place at 104
      weeks from the baseline visit.

      Visual acuity measurement should be performed by trial certified optometrist according to the
      standard ETDRS (Early Treatment of Diabetic Retinopathy Study) protocol. This is to be
      conducted in certified examination rooms.

      Spectral domain OCT (Optical Coherence Tomography) should be used to assess diabetic macular
      oedema and optic disc morphology at each visit. The OCT viewer software should be able to
      provide objective retinal thickness measurement of the central 1mm subfield thickness.
      Technicians should check for segmentation errors with every OCT scan and make appropriate
      manual adjustments.

      OCT machines and designated technicians at each site will be certified prior to study
      commencement. Patients must always be assessed using the same OCT model.

      7-View Fundus Photography and Fluorescein Angiography (FA) will be performed at the screening
      visit to confirm the diagnosis of diabetic macular oedema and assess diabetic retinopathy.

      Additional FAs may be undertaken during subsequent visits should the investigator believe
      that there is a clinical need for it. Investigators at each local site are responsible for FA
      and OCT image interpretation. There will be no centralized image reading centre involved in
      this study.

      IOP (Intraocular Pressure) measurement should be performed with Goldman tonometry either with
      undilated or dilated pupils.

      The primary outcome analysis will be performed to test the differences in the average number
      of intravitreal injections between the two treatment arms up to month 24. This will be
      carried out according to an intent to treat principle.

      The change of visual acuity from baseline to month 24 will be tested for non-inferiority
      against the control arm. We will analyze the stability of visual acuity and CRT using AUC
      (Area Under Curve) Analysis and estimate the average cost of resources utilization for both
      treatment arms.

      Methods of dealing with missing data will follow established techniques, using multiple
      imputation to impute missing data. If necessary sensitivity analyses will be undertaken to
      examine the dependence of the results on the method of imputation.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funder withdrawn funding.
  </why_stopped>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double masking randomized control trial with 2 parallel treatment arms: intervention (Iluvien plus Ranibizumab) vs control (Sham plus Ranibizumab)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>To maintain double-masking, participants assigned to the control arm will receive sham implantation. This will be performed with an empty Luer Lock Syringe without a needle attached to it, that will not penetrate the eye nor deliver any drug.
The Iluvien and the sham injection should be performed by the unmasked investigator. The unmasked investigator should not be involved in any patient assessment in the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Lucentis Injections received in the study eye</measure>
    <time_frame>24 months</time_frame>
    <description>The total number of Lucentis injections needed over 24 months following the intravitreal injection PRN protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in visual acuity</measure>
    <time_frame>Month 24</time_frame>
    <description>Change in ETDRS (Early Treatment of Diabetic Retinopathy Study) best corrected visual acuity from baseline to month 24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintaining at least 20/40 vision</measure>
    <time_frame>Month 24</time_frame>
    <description>Percentage of patients that achieve or maintain 20/40 vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with vision loss</measure>
    <time_frame>Month 24</time_frame>
    <description>Proportion of participants losing 5, 10, 15 ETDRS letters or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with visual gain</measure>
    <time_frame>Month 24</time_frame>
    <description>Proportion of participants gaining at least 5, 10, 15 ETDRS letters or more</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of vision</measure>
    <time_frame>Over 24 months</time_frame>
    <description>Stability of visual acuity over 24 months using Area Under Curve Analysis (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central retinal thickness</measure>
    <time_frame>Month 24</time_frame>
    <description>Central retinal thickness (CRT) change as measured by Spectral Domain OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRT stability</measure>
    <time_frame>Over 24 months</time_frame>
    <description>Stability of CRT over 24 months using AUC analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal thickness variability</measure>
    <time_frame>Over 24 months</time_frame>
    <description>The difference between min and max retinal thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diabetic Retinopathy Severity</measure>
    <time_frame>Between baseline and month 24</time_frame>
    <description>Measured using the ETDRS DRSS (Diabetic Retinopathy Severity Score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of focal laser treatments</measure>
    <time_frame>Over 24 months</time_frame>
    <description>Number of focal laser treatments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Iluvien Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to the Iluvien treatment arm will receive Iluvien 0.19 MG Drug Implant to the study eye under aseptic condition at baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>To maintain double-masking, participants assigned to the control arm will receive Sham Intravitreal Injection at the baseline visit with monthly Ranibizumab Injection [Lucentis] for first three visits followed by monthly Ranibizumab Injection [Lucentis] PRN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iluvien 0.19 MG Drug Implant</intervention_name>
    <description>Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit</description>
    <arm_group_label>Iluvien Arm</arm_group_label>
    <other_name>Fluocinolone Acetonide Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab Injection [Lucentis]</intervention_name>
    <description>Monthly PRN intravitreal injections</description>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_label>Iluvien Arm</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Intravitreal Injection</intervention_name>
    <description>Sham injection without penetrating needle and without drug delivery at baseline visit.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Sham Injection with Luer Lock Syringe</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General

          1. Willingness and the ability to provide informed consent.

          2. Ability and willingness to undertake all scheduled visits, assessment and treatment.

          3. Age 18 years or above.

          4. Documented diagnosis of diabetes mellitus (Type I or Type II) as per WHO (World Health
             Organization) criteria.

          5. Current regular use of oral anti-hyperglycaemia or insulin therapy.

          6. For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods with a failure rate of &lt;1% per
             year during the study duration of 24 months.

        Ocular

          1. Macular thickening due to Diabetic Macular Oedema (DMO) involving the centre of fovea
             as measured by Spectral Domain OCT with CRT of at least 400 microns.

          2. DMO confirmed by clinical examination and fundus fluorescein angiography.

          3. BCVA between 73 to 25 letters inclusive (Snellen equivalent to 6/12 to 6/96) as
             measured using ETDRS protocol at 4 meters.

          4. Pseudophakia in the study eye.

          5. Adequate ocular media clarity and pupillary dilatation allowing for posterior segment
             examination and OCT scanning.

        Exclusion Criteria:

        General

          1. Cerebral vascular accident, transient ischaemic attack or myocardial infarction within
             3 months prior to day 1 (baseline).

          2. Pregnancy or breastfeeding, or intention to become pregnant during the study.

          3. Participation in an investigational trial involving treatment with any drug or devices
             within 3 months prior to day 1 (baseline) and must not be enrolled in another
             investigational trial during their participation in this trial.

          4. Systemic anti-VEGF-base therapies within 3 months prior to day 1 (baseline).

        Ocular

          1. History of prior intravitreal anti-VEGF therapy or steroid implant in the study eye.

          2. History of proliferative diabetic retinopathy.

          3. History of rubeosis or current rubeosis.

          4. History of neovascularization, tractional retinal detachment, retinal vein occlusion,
             or significant pre-retinal fibrosis distorting the macular architecture.

          5. History of retinal detachment or macular hole stage 3 or above.

          6. History of vitreoretinal surgery.

          7. Aphakia.

          8. History of glaucoma or uncontrolled ocular hypertension.

          9. Active or suspected ocular or periocular infection or inflammation, including viral
             diseases of the cornea, conjunctiva and retina, such as active epithelial herpes
             simplex keratitis (dendritic keratitis), varicella, mycobacterial infections, and
             fungal diseases.

         10. Panretinal Photocoagulation (PRP) laser treatment within 3 months prior to day 1.

         11. Macular laser (focal or grid) within 3 months prior to day 1.

         12. YAG (yttrium aluminium garnet) laser capsulotomy laser within 3 months prior to day 1.

         13. Any periocular steroid treatment within 6 months prior to day 1.

         14. Cataract operation within 3 months prior to day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Cheong-Leen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <reference>
    <citation>Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012 Mar 29;366(13):1227-39. doi: 10.1056/NEJMra1005073. Review.</citation>
    <PMID>22455417</PMID>
  </reference>
  <reference>
    <citation>Bunce C, Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond). 2008 Jul;22(7):905-11. Epub 2007 Mar 2.</citation>
    <PMID>17332762</PMID>
  </reference>
  <reference>
    <citation>Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998 Jun;105(6):998-1003.</citation>
    <PMID>9627648</PMID>
  </reference>
  <reference>
    <citation>Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski JW, Bek T, Chen SJ, Dekker JM, Fletcher A, Grauslund J, Haffner S, Hamman RF, Ikram MK, Kayama T, Klein BE, Klein R, Krishnaiah S, Mayurasakorn K, O'Hare JP, Orchard TJ, Porta M, Rema M, Roy MS, Sharma T, Shaw J, Taylor H, Tielsch JM, Varma R, Wang JJ, Wang N, West S, Xu L, Yasuda M, Zhang X, Mitchell P, Wong TY; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64. doi: 10.2337/dc11-1909. Epub 2012 Feb 1. Review.</citation>
    <PMID>22301125</PMID>
  </reference>
  <reference>
    <citation>Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014 Oct 24;(10):CD007419. doi: 10.1002/14651858.CD007419.pub4. Review. Update in: Cochrane Database Syst Rev. 2017 Jun 22;6:CD007419.</citation>
    <PMID>25342124</PMID>
  </reference>
  <reference>
    <citation>Grover D, Li TJ, Chong CC. Intravitreal steroids for macular edema in diabetes. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD005656. doi: 10.1002/14651858.CD005656.pub2. Review.</citation>
    <PMID>18254088</PMID>
  </reference>
  <reference>
    <citation>Goñi FJ, Stalmans I, Denis P, Nordmann JP, Taylor S, Diestelhorst M, Figueiredo AR, Garway-Heath DF. Elevated Intraocular Pressure After Intravitreal Steroid Injection in Diabetic Macular Edema: Monitoring and Management. Ophthalmol Ther. 2016 Jun;5(1):47-61. doi: 10.1007/s40123-016-0052-8. Epub 2016 May 10.</citation>
    <PMID>27164896</PMID>
  </reference>
  <reference>
    <citation>Parrish RK 2nd, Campochiaro PA, Pearson PA, Green K, Traverso CE; FAME Study Group. Characterization of Intraocular Pressure Increases and Management Strategies Following Treatment With Fluocinolone Acetonide Intravitreal Implants in the FAME Trials. Ophthalmic Surg Lasers Imaging Retina. 2016 May 1;47(5):426-35. doi: 10.3928/23258160-20160419-05.</citation>
    <PMID>27183546</PMID>
  </reference>
  <reference>
    <citation>Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003 Sep;110(9):1690-6.</citation>
    <PMID>13129863</PMID>
  </reference>
  <reference>
    <citation>Funatsu H, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005 May;112(5):806-16.</citation>
    <PMID>15878060</PMID>
  </reference>
  <reference>
    <citation>Aiello LP. Angiogenic pathways in diabetic retinopathy. N Engl J Med. 2005 Aug 25;353(8):839-41.</citation>
    <PMID>16120866</PMID>
  </reference>
  <reference>
    <citation>Wang K, Wang Y, Gao L, Li X, Li M, Guo J. Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull. 2008 Aug;31(8):1541-6.</citation>
    <PMID>18670086</PMID>
  </reference>
  <reference>
    <citation>Minassian DC, Owens DR, Reidy A. Prevalence of diabetic macular oedema and related health and social care resource use in England. Br J Ophthalmol. 2012 Mar;96(3):345-9. doi: 10.1136/bjo.2011.204040. Epub 2011 May 20.</citation>
    <PMID>21602478</PMID>
  </reference>
  <reference>
    <citation>Arevalo JF, Lasave AF, Wu L, Acon D, Farah ME, Gallego-Pinazo R, Alezzandrini AA, Fortuna V, Quiroz-Mercado H, Salcedo-Villanueva G, Maia M, Serrano M, Rojas S; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group. Br J Ophthalmol. 2016 Dec;100(12):1605-1610. doi: 10.1136/bjophthalmol-2015-307950. Epub 2016 Feb 24.</citation>
    <PMID>26912377</PMID>
  </reference>
  <reference>
    <citation>Wells JA, Glassman AR, Ayala AR, Jampol LM, Bressler NM, Bressler SB, Brucker AJ, Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW; Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial. Ophthalmology. 2016 Jun;123(6):1351-9. doi: 10.1016/j.ophtha.2016.02.022. Epub 2016 Feb 27.</citation>
    <PMID>26935357</PMID>
  </reference>
  <reference>
    <citation>Mehta H, Gillies M, Fraser-Bell S. Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema. Ther Adv Chronic Dis. 2015 Sep;6(5):234-45. doi: 10.1177/2040622315590319. Review.</citation>
    <PMID>26336592</PMID>
  </reference>
  <reference>
    <citation>Hernández-Bel L, Cervera-Taulet E, Navarro-Palop C, Castro-Navarro V, Chiarri-Toumit C, Montero-Hernández J. Sequential Dexamethasone and Aflibercept Treatment in Patients with Diabetic Macular Edema: Structural and Functional Outcomes at 52 Weeks. Ophthalmologica. 2019;241(2):98-104. doi: 10.1159/000489345. Epub 2018 Jul 11.</citation>
    <PMID>29996128</PMID>
  </reference>
  <reference>
    <citation>Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, Garretson B, Gupta A, Hariprasad SM, Bailey C, Reichel E, Soubrane G, Kapik B, Billman K, Kane FE, Green K; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012 Oct;119(10):2125-32. doi: 10.1016/j.ophtha.2012.04.030. Epub 2012 Jun 21.</citation>
    <PMID>22727177</PMID>
  </reference>
  <reference>
    <citation>Cunha-Vaz J, Ashton P, Iezzi R, Campochiaro P, Dugel PU, Holz FG, Weber M, Danis RP, Kuppermann BD, Bailey C, Billman K, Kapik B, Kane F, Green K; FAME Study Group. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology. 2014 Oct;121(10):1892-903. doi: 10.1016/j.ophtha.2014.04.019. Epub 2014 Jun 14.</citation>
    <PMID>24935282</PMID>
  </reference>
  <reference>
    <citation>Shimura M, Yasuda K, Minezaki T, Noma H. Reduction in the frequency of intravitreal bevacizumab administrations achieved by posterior subtenon injection of triamcinolone acetonide in patients with diffuse diabetic macular edema. Jpn J Ophthalmol. 2016 Sep;60(5):401-7. doi: 10.1007/s10384-016-0458-9. Epub 2016 Jun 15.</citation>
    <PMID>27306783</PMID>
  </reference>
  <reference>
    <citation>Prünte C, Fajnkuchen F, Mahmood S, Ricci F, Hatz K, Studnička J, Bezlyak V, Parikh S, Stubbings WJ, Wenzel A, Figueira J; RETAIN Study Group. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016 Jun;100(6):787-95. doi: 10.1136/bjophthalmol-2015-307249. Epub 2015 Oct 9.</citation>
    <PMID>26453639</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>December 19, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Eye</keyword>
  <keyword>Macular Oedema</keyword>
  <keyword>Intravitreal Injection</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>Fluocinolone Acetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluocinolone Acetonide</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

